Evidence map›Paper›PMID 40652177›Full record

ArticleBMC infectious diseases2025

Drug resistance of Mycobacterium tuberculosis to linezolid and delamanid: a case report from Bukavu, Democratic Republic of Congo.

Bertin C Bisimwa, Esto Bahizire, Maja Kiselinova, Valéry Byela, Jean Claude S Ngabonziza, François Hakizayezu, Docteur Runyambo, Conor J Meehan, Wim Mulders, Isabel Cuella-Martin and 5 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Bertin C BisimwaCenter for Tropical Diseases & Global Health, Université Catholique de Bukavu, Bukavu, South Kivu, Congo. bcasinga@gmail.com.
Esto BahizireCenter for Tropical Diseases & Global Health, Université Catholique de Bukavu, Bukavu, South Kivu, Congo.
Maja KiselinovaDepartment of Internal Medicine, Ghent University Hospital, Ghent, Belgium.
Valéry ByelaCenter for Tropical Diseases & Global Health, Université Catholique de Bukavu, Bukavu, South Kivu, Congo.
Jean Claude S NgabonzizaResearch Innovation and Data Science Division, Rwanda Biomedical Centre, Kigali, Rwanda.
François HakizayezuRwanda Biomedical Centre, National Laboratory Division, Kigali, Rwanda.
Docteur RunyamboRwanda Biomedical Centre, National Laboratory Division, Kigali, Rwanda.
Conor J MeehanMycobacteriology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Wim MuldersMycobacteriology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Isabel Cuella-MartinMycobacteriology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Leen RigoutsMycobacteriology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Freddy BirembanoNational Tuberculosis Program, Kinshasa, Kinshasa, Congo.
Steven CallensDepartment of Internal Medicine, Ghent University Hospital, Ghent, Belgium.
Bouke C de JongMycobacteriology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Michel KaswaNational Tuberculosis Program, Kinshasa, Kinshasa, Congo.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The emergence of resistance is of great concern in the control of TB, especially to the new and repurposed drugs needed for the treatment of rifampicin resistance. We report a patient from South Kivu in the Eastern Democratic Republic of the Congo with primary resistance to delamanid and linezolid without treatment experience with these drugs. The identification of novel resistance mutations raises concerns about the potential global spread and poor outcomes of the WHO-recommended oral treatment regimens, highlighting the need for the urgent rollout of DST.

Indexed as

Antitubercular AgentsDrug Resistance, BacterialLinezolidMycobacterium tuberculosisNitroimidazolesOxazolesTuberculosis, Multidrug-ResistantAdultDemocratic Republic of the CongoHumansMaleMicrobial Sensitivity TestsAntitubercular AgentsLinezolidNitroimidazolesOPC-67683OxazolesDrug resistanceLinezolid and DelamanidNovel mutations

Identifiers

PMID40652177
PMCPMC12255050

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.